Medical Devices

With a history of beating expectations and a flurry of strategic moves, Quest Diagnostics' July 23rd earnings report is a key vital sign for the entire diagnostics sector.

A new survey reveals Tennessee seniors delay hearing care for years due to cost fears, risking cognitive decline and falls. But are the solutions already here?

The communications firm adds three seasoned experts, a strategic move to guide biotech and pharma clients through increasingly volatile capital markets.

With a key regulatory win in the UAE, WAT Medical is set to introduce its drug-free neuromodulation devices to a booming Middle Eastern healthcare market.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

New research reveals that custom 3D braces can actively correct spinal curves, not just prevent them from worsening. This paradigm shift in non-surgical care offers new hope.

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

With $1.25M in new funding, Avricore Health isn't just raising capital; it's accelerating a strategic pivot to the lucrative UK market for its HealthTab platform.

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

Milan-based WISE secured €30M to advance its stretchable neuro-implants, aiming to solve a critical dilemma in chronic pain treatment and neurotechnology.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

FiberSense AG’s new 28-day CGM sensor just won European approval, challenging market leaders. But the real growth signal is its plan to move beyond glucose.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Skin Analytics' DERM Zero is the first AI to get Class III certification for autonomous skin cancer checks on a smartphone, promising to transform access.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?